Women's Health

The FDA approves sex-drive pill, Addyi

The FDA approves sex-drive pill, Addyi

By

Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.

Bad ad watchdog slams Kardashian's social-media post

Bad ad watchdog slams Kardashian's social-media post

By

The FDA said Kim Kardashian West's promotion of morning-sickness pill Diclegis misbranded the product by understating its risks.

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

By

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

By

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

By

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

By

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Study shows impact of the "Angelina Jolie effect"

Study shows impact of the "Angelina Jolie effect"

By

AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.

Pfizer Ibrance is first approved CDK inhibitor

Pfizer Ibrance is first approved CDK inhibitor

By

The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.

Pfizer cancer drug skips FDA advisory panel

Pfizer cancer drug skips FDA advisory panel

By

The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.

Pfizer brings humor to menopause marketing

Pfizer brings humor to menopause marketing

The new approach shows "The Talk" has a sequel.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

By

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

Five things for pharma marketers to know: Wednesday, December 3

Five things for pharma marketers to know: Wednesday, December 3

By By

An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.

Insurer's maternity app rewards healthy behaviors

Insurer's maternity app rewards healthy behaviors

By

United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

By

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Pfizer gets palbo review date

Pfizer gets palbo review date

By

The FDA will vote for or against the breast cancer drug by April 13, 2015.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

By

The drugmaker is poised to cut 14 pipeline projects loose.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.

FDA tackles women's sexual health

The regulator and patients will chat for two days in October.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

NIH: HPV test beats Pap for cancer assessment

HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.

ACP says no need for pelvic exams

The American College of Physicians says most women do not need an annual pelvic exam. The American College of Obstetrics and Gynecologists disagrees.

Panel votes against AZ's olaparib

Panel votes against AZ's olaparib

By

An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.

Campaigners want FDA to focus on women's sexual health

Campaigners want FDA to focus on women's sexual health

By

A coalition of organizations, including pharmaceutical company Sprout, kicked off a campaign urging the FDA to pay as much attention to women's sexual dysfunction needs as it does to men's.

KV rebrands, becomes Lumara Health

KV rebrands, becomes Lumara Health

By

The post-Chapter 11 pharmaceutical company unveiled its new name Thursday.

Bayer encourages daily calcium with a side of defiance

Its "Beauty is Bone Deep" campaign looks at beauty from the inside.

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

By

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

By

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

FDA wants parents to back off fetus selfies

The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.

Study shows HPV vax impact

Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.